• Home
  • About
    • Psychedelic For Healthy People
    • Psilocybin (Magic Mushrooms)
    • Ayahuasca (Chacruna – Kaapi – Yajé)
    • MDMA (MDA – Sassafras)
    • Peyote Mescaline (Huachuma)
    • Kambo – Amazonian Frog
    • 5-MeO-DMT (Toad Medicine)
    • Rapé And Sacred Tobacco
    • Iboga (Ibogaine)
    • LSD (Lysergic Acid Diethylamide)
    • Cannabis (Marijuana)
    • Ketamine
    • Psychedelic Integration
    • Psychedelics Advocates
    • Frequently Asked Questions
    • Mental Health Symptoms
    • Substances Test Kits
    • Manifesto
  • Treatments
    • Latest Psychedelic Research
    • Addiction
    • Alcoholism
    • Anxiety
    • Bipolar Disorder
    • Cancer
    • Cluster Headaches
    • Depression
    • End Of Life
    • OCD
    • Neuropathy
    • Pain
    • Parkinson’s Disease
    • PTSD
    • Smoking
    • Help Treat Mental Illness
  • Microdosing
    • What is Microdosing?
    • Microdosing Magic Mushrooms
    • Microdosing LSD
    • Microdosing MDMA
    • Microdosing Ayahuasca
    • Microdosing Mescaline
    • Microdosing Cannabis
    • Microdosing Ibogaine
  • Resources
    • Past Events
    • ALL Locations
    • DMT Psychoactive Plants
    • Medical Trials And Research
    • Psychedelic Research
    • EntheoPodcasts
    • In The News
    • Books On Psychedelics
    • Related Videos
    • EntheoResources
    • Terence McKenna
    • What Is Psychedelic Art?
    • Useful Links
    • Movies & Documentaries
    • Michael Pollan
Contact
  • Follow
  • Follow
  • Follow
  • Follow

Oregon to officially vote on legalizing psychedelic psilocybin therapy

by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana, CBC, Psilocybin Magic Mushroom

The state of Oregon will officially vote on legalizing psilocybin psychotherapy in the upcoming November election, after well over 150,000 signatures were collected to secure the landmark ballot measure. The initiative focuses on licensed and regulated...

Psilocybin & OCD: Can psychedelics treat obsessive compulsive disorder?

by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana, CBC, Psilocybin Magic Mushroom

A new review from neuroethicist Eddie Jacobs, and published in the Journal of Psychedelic Studies, is suggesting psilocybin may have great potential as a treatment for obsessive-compulsive disorder (OCD). Jacobs, from King’s College London and the University of...

World-first clinical trial finds CBD can help treat cannabis addiction

by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Cannabis Marijuana, CBC

Positive results from the world’s first clinical trial testing the potential for cannabidiol (CBD) to treat cannabis addiction suggest daily use of medical-grade CBD is both safe and effective at reducing problematic cannabis consumption. The researchers quickly...

Canada grants first legal exemptions for psilocybin use in 50 years

by EmpathiCSubstanceS | Apr 25, 2021 | Psilocybin Magic Mushroom

After waiting more than 100 days for a response, four terminally ill cancer patients have now been approved to use psilocybin to treat end-of-life distress. These patients will be the first to legally use the psychedelic in Canada for almost half a century following...

CBD increases blood flow in regions of the brain linked to memory

by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana, CBC, MDMA Sassafras Molly

A new study, led by researchers from University College London, is offering some of the first robust evidence showing how cannabidiol (CBD), a key compound in cannabis, increases cerebral blood flow in memory processing regions of the brain such as the hippocampus....
« Older Entries
Next Entries »

IMPORTANT NOTICE:

This community is being designed as a secure space. It is not a place to seek, encourage, or participate in the procurement of controlled substances. Do not bring, buy, sell, transfer, or arrive on any illegal substances, or swap information on how to buy them. Attendees and/or members of this community who violate these basic house rules will be removed from the community and will not be allowed to attend future events.

Psychedelic Research

Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study

Aug 11, 2022

Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session...

Potential Psychiatric Uses for MDMA

Aug 11, 2022

In MDMA studies, participants report improved self‐knowledge, sleep regulation, accuracy in perceiving mental states of others, coping strategies, emotion regulation, and cognitive insights. Objective measures support attenuated impact of social rejection and reduced...

The cognitive effects of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) are associated with improvements in depression and anxiety conditions

Aug 11, 2022

Of those reporting a history of being diagnosed with depression (n=149; 41%) or anxiety (n=173; 48%), most reported symptoms were improved (depression=81%; anxiety=79%) following 5-MeO-DMT use and relatively fewer reported symptoms remained the same (depression=17%;...

Psychedelic Medicine

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

© 2025| All Rights Reserved, EntheoMedicine Community
  • Follow
  • Follow
  • Follow
  • Follow